Roche has taken a lead in the oral SERD category of breast cancer therapies with the presentation of new data at ESMO showing ...

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

In an era where the biopharmaceutical landscape is rapidly evolving, a comprehensive approach to demonstrating and ...

At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with ...

Interestingly, while only 16% of oncology researchers reported using AI in biomarker detection and assessment at the time of ...

The Galleri multi-cancer early detection (MCED) test – which looks for around 50 different types – achieved a seven-fold ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

Millions of women worldwide live with endometriosis, which causes symptoms like pain and extreme tiredness and, if untreated, ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...